HIGHLIGHTS
- who: Shen Zhao and collaborators from the Asahikawa Medical, Japan have published the research work: Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer, in the Journal: (JOURNAL) of 30/Nov/2015
- what: IP paclitaxel 80 mg/m2 day 1 plus mFOLFOX6 (ipPOF) was selected for the current trial with ivPOF to clearly delineate their safety and efficacy compared with mFOLFOX6 in participants with uAGC. The study shows that, compared with mFOLFOX6, IV or IP paclitaxel plus mFOLFOX6 significantly improves PFS and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.